May 07, 2025 / 09:00AM GMT
Cecilia de Leeuw - C Rad AB - President, Chief Executive officer and Independent Director
Welcome to our Q1 presentation.
We started the year with a solid quarter in a wait and see market. As most of C Rad is active within radiation therapy, and more than 50% of all cancer patients undergo radiation therapy at some point of the treatment.
And our focus at C Rad is the M2M surface guided workflow from CT room to treatment room, where our surface guided radiation technology or SGRT supports that the dose reaches the tumor and not the healthy tissue of the patient.
But Let me first zoom out and remind you of C Rad 's long-term strategy and priorities. Also, as many of we have announced our medium-term financial targets, which I will come back to later on in the presentation.
So first, I will take you through our progress for Q1.
Let me take you through the slide, left to right. So first, I will start to the left with the market. We see C Rad have a global reach and expanding step by step to grow our sales.
And in line with our ambition to grow in the
Q1 2025 C Rad AB Earnings Call Transcript
May 07, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers